Duke Perspectives at AHA 2016

DUKE PERSPECTIVES
AHA Conference Coverage
November 14 to 17, 2016

Duke attended the 2016 Scientific Sessions of the American Heart Association held November 14 to 17, in New Orleans. Read what you may have missed in our daily recaps.

Early ambulation may benefit patients with HF
November 14, 2016
Hospitals with the highest rates of early ambulation had the shortest lengths of stay after stratification. [Read more]

Use of mineralocorticoids associated with decreased risk of rehospitalization at 1 and 3 years
November 14, 2016
Mineralocorticoid receptor antagonists may be safe and beneficial for use in certain patients with HF and other comorbidities. [Read more]

Ticagrelor not superior to clopidogrel for reducing cardiovascular events
November 14, 2016
Duke researcher says these results demonstrate the hazards of extrapolating evidence from coronary artery disease populations to PAD. [Read more]

Extended-duration betrixaban reduces symptomatic VTE in select hospitalized patients
November 15, 2016
Easing the total burden of VTE among patients taking betrixaban could free up health care resources and help alleviate costs. [Read more]

Rivaroxaban reduces risk of bleeding in patients with AF undergoing PCI with stenting
November 15, 2016
A rivaroxaban-based strategy reduced the risk of clinically significant bleeding compared with warfarin-based treatment. [Read more]

Study identifies characteristics of FH in children and adolescents
November 15, 2016
Nearly one-third of youth with FH have a family history of premature myocardial infarction. [Read more]

Apo-A1 is well tolerated and may be safe in patients after recent MI
November 16, 2016
Apo-A1 has the potential to reduce major adverse cardiovascular events. [Read more]

Format of risk communications influences perceived risk and willingness for therapy
November 16, 2016
Communicating lifetime rather than short-term risk estimates has a greater influence on how patients perceive their risk of CVD. [Read more]

Cause-specific mortality among patients taking anticoagulation for AF
November 16, 2016
Sudden cardiac death and HF are the most common cardiovascular-related deaths in patients with AF taking an oral anticoagulant. [Read more]

Extended-duration betrixaban reduces stroke in medically ill hospitalized patients
November 17, 2016
Betrixaban significantly reduced the rate of any stroke compared with thromboprophylactic enoxaparin. [Read more]

Routine use of high-dose spironolactone not beneficial in acute HF
November 17, 2016
Although study findings do not support the routine use of spironolactone, patients with a higher ejection fraction may gain some benefit. [Read more]

Oral iron supplementation does not improve functional capacity in chronic HF
November 17, 2016
Although oral supplementation with iron is safe and readily available, study results suggest that it does not improve functional capacity in patients with HF and reduced ejection fraction. [Read more]